Hypertension in pregnancy
Hypertension in pregnancy
复制标题
DOI：
10.1007/s11906-005-0068-2
复制
发表时间：
2005-10-01
影响因子：
5.6
通讯作者：
McFarlane, SI
中科院分区：
文献类型：
--
作者：
Mugo, M;Govindarajan, G;McFarlane, SI
妊娠期高血压对产妇和新生儿的发病率和死亡率都有很大影响。在不同形式的妊娠高血压综合征中，先兆子痫-子痫对发病率和死亡率的影响最大。慢性高血压可能导致早产和小于胎龄儿，即使是轻度到中度。慢性高血压是叠加性子痫前期的危险因素，并导致较高的不良结局发生率。子痫前期是一种多系统疾病，被认为是由胎盘血流异常和内皮功能障碍引起的，最终导致多器官衰竭。先兆子痫在社会经济上处于不利地位的少数族裔妇女中更为常见。妊娠期高血压疾病的药物治疗因担心母亲和胎儿的安全而受到限制。虽然重度高血压的治疗没有争议，但对于妊娠期轻至中度高血压的药物治疗的理论基础还没有达成共识。
Hypertension in pregnancy contributes significantly to both maternal and neonatal morbidity and mortality. Among different forms of pregnancy-associated hypertension, preeclampsia-eclampsia has the highest impact on morbidity and mortality. Chronic hypertension may result in preterm and small for gestational age infants, even when it is mild-to-moderate. Chronic hypertension is a risk factor for superimposed preeclampsia and results in higher rates of adverse outcome. Preeclampsia is a multisystemic disease that is thought to be initiated by abnormalities in placental perfusion and endothelial dysfunction, ultimately resulting in multiorgan failure. Preeclampsia is more common in women of minority ethnicity who are socioeconomically disadvantaged. Pharmacologic therapy for hypertensive disorders in pregnancy is limited by concerns regarding the safety of both mother and fetus. Although treatment of severe hypertension is not debated, there is no consensus on the rationale for pharmacologic therapy of mild-to-moderate hypertension in pregnancy.